ReviewJournal of nuclear medicine : official publication, Society of Nuclear Medicine2009
18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization.
Review in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic performance of whole-body [European radiology · 2024Pooled it
- Local production of lactate, ribose phosphate, and amino acids within human triple-negative breast cancer.Med (New York, N.Y.) · 2021Trial
- ¹⁸F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer.European journal of nuclear medicine and molecular imaging · 2011Trial
- Coronary artery disease imaging with total-body PET.The British journal of radiology · 2026Review
- SLC Transporter-Mediated Functional Imaging in Cancer Diagnosis.Biomolecules · 2026Review
- Preventive Effect of Butyrate in Colon Cancer Cell Metabolism.International journal of molecular sciences · 2026Article
- Case Report: a hypermetabolic mediastinal mass (SUVmax 16.7) mimicking malignancy with spontaneous resolution: an inflammatory myofibroblastic proliferation and diagnostic pitfall.Frontiers in oncology · 2026Article
- Diagnosis of cardiac sarcoidosis using glucose metabolic rate from four-dimensionalAnnals of nuclear medicine · 2025Article
- Baseline total lesion glycolysis identifies high-risk patients with immunosuppressive signatures in early-stage natural killer/T-cell lymphoma.The oncologist · 2025Article
- Article
- Glucose metabolic rate from four-dimensional [European radiology · 2025Article
- The implication of aberrant NRF2 activation in management of female cancers.Frontiers in oncology · 2025Review
- Free Methylglyoxal as a Metabolic New Biomarker of Tumor Cell Proliferation in Cancers.Cancers · 2024Article
- A mathematical model for pancreatic cancer during intraepithelial neoplasia.Royal Society open science · 2024Article
- TRIP6 a potential diagnostic marker for colorectal cancer with glycolysis and immune infiltration association.Scientific reports · 2024Article
- Exploring the correlation between HER2 alterations andJournal of cancer research and clinical oncology · 2023Article
- DARS2 overexpression is associated with PET/CT metabolic parameters and affects glycolytic activity in lung adenocarcinoma.Journal of translational medicine · 2023Article
- Development and External Validation ofCancers · 2023Article
- Synthesis, radiolabeling, and evaluation of 68Ga-labeled aminoquinoxaline derivative as a potent PFKFB3-targeted PET tracer.Frontiers in chemistry · 2023Article
- GPC3-targeted immunoPET imaging of hepatocellular carcinomas.European journal of nuclear medicine and molecular imaging · 2022Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
It is hoped that in the not too distant future, noninvasive imaging-based molecular interrogation and characterization of tumors can improve our fundamental understanding of the dynamic biologic behavior of cancer. For example, the new dimension of diagnostic information that is provided by (18)F-FDG PET has led to improved clinical decision making and management changes in a substantial number of patients with cancer. In this context, the aim of this review is to bring together and summarize the current data on the correlation between the underlying molecular biology and the clinical observations of tumor (18)F-FDG accumulation in 3 major human cancers: lung, breast, and colon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.